ZA200510257B - Chinazoline derivatives as Aurora kinase inhibitors - Google Patents
Chinazoline derivatives as Aurora kinase inhibitors Download PDFInfo
- Publication number
- ZA200510257B ZA200510257B ZA200510257A ZA200510257A ZA200510257B ZA 200510257 B ZA200510257 B ZA 200510257B ZA 200510257 A ZA200510257 A ZA 200510257A ZA 200510257 A ZA200510257 A ZA 200510257A ZA 200510257 B ZA200510257 B ZA 200510257B
- Authority
- ZA
- South Africa
- Prior art keywords
- salkyl
- compound
- ester
- hydrogen
- 4alkyl
- Prior art date
Links
- 239000003719 aurora kinase inhibitor Substances 0.000 title description 2
- 125000003790 chinazolinyl group Chemical group 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims description 48
- 229910052739 hydrogen Inorganic materials 0.000 claims description 47
- 239000001257 hydrogen Substances 0.000 claims description 47
- 150000001875 compounds Chemical class 0.000 claims description 45
- 150000002431 hydrogen Chemical class 0.000 claims description 41
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 34
- 229910052757 nitrogen Inorganic materials 0.000 claims description 33
- 150000003839 salts Chemical class 0.000 claims description 32
- 150000002148 esters Chemical class 0.000 claims description 31
- 125000001475 halogen functional group Chemical group 0.000 claims description 31
- 125000000623 heterocyclic group Chemical group 0.000 claims description 29
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 125000001424 substituent group Chemical group 0.000 claims description 21
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 18
- 229940002612 prodrug Drugs 0.000 claims description 17
- 239000000651 prodrug Substances 0.000 claims description 17
- -1 arylC Chemical group 0.000 claims description 15
- 125000003342 alkenyl group Chemical group 0.000 claims description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 9
- 125000006413 ring segment Chemical group 0.000 claims description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- 125000000304 alkynyl group Chemical group 0.000 claims description 8
- 125000002619 bicyclic group Chemical group 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 125000002950 monocyclic group Chemical group 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 4
- 210000000481 breast Anatomy 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 4
- 230000003463 hyperproliferative effect Effects 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 210000003932 urinary bladder Anatomy 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 230000022131 cell cycle Effects 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 102100032306 Aurora kinase B Human genes 0.000 description 5
- 102000003989 Aurora kinases Human genes 0.000 description 5
- 108090000433 Aurora kinases Proteins 0.000 description 5
- 108091007914 CDKs Proteins 0.000 description 5
- 101000798306 Homo sapiens Aurora kinase B Proteins 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 150000003246 quinazolines Chemical class 0.000 description 4
- 102000004000 Aurora Kinase A Human genes 0.000 description 3
- 108090000461 Aurora Kinase A Proteins 0.000 description 3
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 3
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000005441 aurora Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VDDAVZWCRBHDLQ-UHFFFAOYSA-N 2-phenylquinazoline Chemical class C1=CC=CC=C1C1=NC=C(C=CC=C2)C2=N1 VDDAVZWCRBHDLQ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 108090000749 Aurora kinase B Proteins 0.000 description 1
- 102000004228 Aurora kinase B Human genes 0.000 description 1
- 102100026630 Aurora kinase C Human genes 0.000 description 1
- 108090000805 Aurora kinase C Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 108090000259 Cyclin D Proteins 0.000 description 1
- 102000003910 Cyclin D Human genes 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Divinylene sulfide Natural products C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 108700020490 Drosophila S Proteins 0.000 description 1
- 108700019348 Drosophila aurA Proteins 0.000 description 1
- 108010093502 E2F Transcription Factors Proteins 0.000 description 1
- 102000001388 E2F Transcription Factors Human genes 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108700025701 Retinoblastoma Genes Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 231100001075 aneuploidy Toxicity 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 108700042656 bcl-1 Genes Proteins 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 210000003793 centrosome Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 231100000722 genetic damage Toxicity 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 230000025053 regulation of cell proliferation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003557 thiazoles Chemical class 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 150000003577 thiophenes Chemical class 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03291463 | 2003-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200510257B true ZA200510257B (en) | 2007-05-30 |
Family
ID=33522456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200510257A ZA200510257B (en) | 2003-06-17 | 2005-12-15 | Chinazoline derivatives as Aurora kinase inhibitors |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20060178382A1 (es) |
| EP (1) | EP1644361A1 (es) |
| JP (1) | JP2006527748A (es) |
| KR (1) | KR20060011891A (es) |
| CN (1) | CN1835945A (es) |
| AR (1) | AR045694A1 (es) |
| AU (1) | AU2004249477A1 (es) |
| BR (1) | BRPI0411503A (es) |
| CA (1) | CA2529250A1 (es) |
| IL (1) | IL172375A0 (es) |
| MX (1) | MXPA05013825A (es) |
| NO (1) | NO20055891L (es) |
| TW (1) | TW200505452A (es) |
| UY (1) | UY28366A1 (es) |
| WO (1) | WO2004113324A1 (es) |
| ZA (1) | ZA200510257B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004232527A1 (en) * | 2003-04-16 | 2004-11-04 | Astrazeneca Ab | Chemical compounds |
| ES2308182T3 (es) * | 2003-06-02 | 2008-12-01 | Astrazeneca Ab | Derivadosde (3-((quinazolin-4-il)amino)-1h-pirazol-1-il)acetamida y compuestos relacionados como inhibidores de quinasas aurora para el tratamiento de enfermedades proliferativas tales como el cancer. |
| CN101072758B (zh) | 2004-10-12 | 2013-07-31 | 阿斯利康(瑞典)有限公司 | 喹唑啉衍生物 |
| EP1812439B2 (en) | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| WO2006104971A1 (en) * | 2005-03-28 | 2006-10-05 | Bristol-Myers Squibb Company | Atp competitive kinase inhibitors |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| UY30183A1 (es) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
| JP2009528335A (ja) * | 2006-03-02 | 2009-08-06 | アストラゼネカ アクチボラグ | キナゾリン誘導体 |
| CA2652634A1 (en) * | 2006-05-18 | 2007-11-29 | Amphora Discovery Corporation | Certain substituted quinolones, compositions, and uses thereof |
| GB0619342D0 (en) * | 2006-09-30 | 2006-11-08 | Vernalis R&D Ltd | New chemical compounds |
| US20100120717A1 (en) | 2006-10-09 | 2010-05-13 | Brown Jason W | Kinase inhibitors |
| US20110033461A1 (en) * | 2008-03-12 | 2011-02-10 | Vladimir Ratushny | Combination Therapy for the Treatment of Cancer |
| MX2019012847A (es) * | 2017-04-27 | 2022-01-07 | Astrazeneca Ab | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer. |
| WO2018197643A1 (en) * | 2017-04-27 | 2018-11-01 | Astrazeneca Ab | Phenoxyquinazoline compounds and their use in treating cancer |
| KR20190043842A (ko) | 2017-10-19 | 2019-04-29 | 건국대학교 산학협력단 | 피리미딘-2-아민 유도체, 이의 제조방법 및 이를 포함하는 항암제 |
| CN110372666B (zh) * | 2018-04-13 | 2022-11-08 | 华东理工大学 | 喹唑啉类化合物作为egfr三突变抑制剂及其应用 |
| US20230063230A1 (en) * | 2019-02-19 | 2023-03-02 | The Regents Of The University Of California | Nurr1 receptor modulators |
| KR102061458B1 (ko) | 2019-08-14 | 2019-12-31 | 건국대학교 산학협력단 | 피리미딘-2-아민 유도체, 이의 제조방법 및 이를 포함하는 항암제 |
| CN112939948B (zh) * | 2019-12-11 | 2022-05-17 | 苏州美诺医药科技有限公司 | 新型含喹唑啉类化合物及其中间体与应用 |
| CN113200964B (zh) * | 2021-04-25 | 2022-07-05 | 南方医科大学南方医院 | 18f标记的egfr正电子显像剂及其制备方法与应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9922171D0 (en) * | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
| PL360439A1 (en) * | 2000-06-28 | 2004-09-06 | Astrazeneca Ab | Substituted quinazoline derivatives and their use as inhibitors |
| AU2002350105A1 (en) * | 2001-06-21 | 2003-01-08 | Ariad Pharmaceuticals, Inc. | Novel quinazolines and uses thereof |
| IL162541A0 (en) * | 2001-12-24 | 2005-11-20 | Astrazeneca Ab | Substituted quinazoline derivatives as inhibitors of aurora kinases |
-
2004
- 2004-06-07 TW TW093116336A patent/TW200505452A/zh unknown
- 2004-06-14 EP EP04736769A patent/EP1644361A1/en not_active Withdrawn
- 2004-06-14 BR BRPI0411503-1A patent/BRPI0411503A/pt not_active Application Discontinuation
- 2004-06-14 CN CNA2004800231405A patent/CN1835945A/zh active Pending
- 2004-06-14 JP JP2006516425A patent/JP2006527748A/ja active Pending
- 2004-06-14 CA CA002529250A patent/CA2529250A1/en not_active Abandoned
- 2004-06-14 AU AU2004249477A patent/AU2004249477A1/en not_active Abandoned
- 2004-06-14 MX MXPA05013825A patent/MXPA05013825A/es unknown
- 2004-06-14 KR KR1020057024207A patent/KR20060011891A/ko not_active Application Discontinuation
- 2004-06-14 US US10/560,659 patent/US20060178382A1/en not_active Abandoned
- 2004-06-14 WO PCT/GB2004/002564 patent/WO2004113324A1/en active Application Filing
- 2004-06-17 UY UY28366A patent/UY28366A1/es not_active Application Discontinuation
- 2004-06-17 AR ARP040102113A patent/AR045694A1/es unknown
-
2005
- 2005-12-05 IL IL172375A patent/IL172375A0/en unknown
- 2005-12-12 NO NO20055891A patent/NO20055891L/no not_active Application Discontinuation
- 2005-12-15 ZA ZA200510257A patent/ZA200510257B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20060011891A (ko) | 2006-02-03 |
| AU2004249477A1 (en) | 2004-12-29 |
| WO2004113324A1 (en) | 2004-12-29 |
| CN1835945A (zh) | 2006-09-20 |
| MXPA05013825A (es) | 2006-02-28 |
| CA2529250A1 (en) | 2004-12-29 |
| NO20055891L (no) | 2006-02-07 |
| US20060178382A1 (en) | 2006-08-10 |
| UY28366A1 (es) | 2005-01-31 |
| BRPI0411503A (pt) | 2006-07-25 |
| JP2006527748A (ja) | 2006-12-07 |
| EP1644361A1 (en) | 2006-04-12 |
| AR045694A1 (es) | 2005-11-09 |
| TW200505452A (en) | 2005-02-16 |
| IL172375A0 (en) | 2009-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200510257B (en) | Chinazoline derivatives as Aurora kinase inhibitors | |
| ZA200508372B (en) | Quinazoline derivatives for treatment of cancer | |
| ZA200404923B (en) | Substituted quinazoline derivatives as inhibitors of aurora kinases | |
| Bolanos-Garcia | Aurora kinases | |
| US6831071B2 (en) | Synthesis of biologically active compounds in cells | |
| Mountzios et al. | Aurora kinases as targets for cancer therapy | |
| Morel et al. | Signal transduction pathways: new targets for treating rheumatoid arthritis | |
| Portella et al. | Aurora B: a new prognostic marker and therapeutic target in cancer | |
| Kurio et al. | Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo | |
| US9018191B2 (en) | Phosphonoxy quinazoline derivatives and their pharmaceutical use | |
| EP1575966B1 (en) | Therapeutic quinazoline derivatives | |
| JP2007529421A5 (es) | ||
| JP2020530467A (ja) | 癌転移を処置するためにキナーゼを標的とする方法 | |
| CA2858789A1 (en) | Treatment of inflammation | |
| Colombo et al. | ‘Click’synthesis of a triazole-based inhibitor of Met functions in cancer cells | |
| CN110430896A (zh) | 用于增加血浆2′-脱氧尿苷(dUrd)和胸苷酸合成酶抑制的方法 | |
| Xiao et al. | Pectolinarigenin prevents bone loss in ovariectomized mice and inhibits RANKL‐induced osteoclastogenesis via blocking activation of MAPK and NFATc1 signaling | |
| US20090253616A1 (en) | Combination therapy for the treatment of cancer | |
| US20060135541A1 (en) | (3-((Quinazolin-4-yl) amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer | |
| JP2001515916A (ja) | 悪性および伝染性疾患の治療用にニコチンアミド・アデニン・ジヌクレオチドならびにその類似物を用いる治療法 | |
| Baranyi et al. | Next generation lipophilic bisphosphonate shows antitumor effect in colorectal cancer in vitro and in vivo | |
| US8952019B2 (en) | Methods of using selective chemotherapeutic agents for targeting tumor cells | |
| Gong et al. | 3D culture system containing gellan gum restores oncogene dependence in ROS1 rearrangements non-small cell lung cancer | |
| Fukushima et al. | Roles of RAS and BRAF mutations in thyroid carcinogenesis | |
| Xia et al. | PKCδ survival signaling in cells containing an activated p21Ras protein requires PDK1 |